Table 2.
Non-compartmental analysis of interferon-α: Mean ± S.D. (CV%)
| Group | Dose | Formulation | Cmax (pg/mL) | Median Tmax (h) | AUClast (ng·h/mL) |
|---|---|---|---|---|---|
| Controla (N=8) |
3 MIU |
Roferon-A® |
43.27 ± 9.804 (22.66%) |
6 |
0.9664 ± 0.9322 (96.46%) |
| 1 (N=6) |
9 MIU |
SR-IFN-α |
28.33 ± 9.656 (34.08%) |
18 |
2.072 ± 1.134 (54.73%) |
| 2 (N=6) |
18 MIU |
SR-IFN-α |
62.12 ± 15.93 (25.64%) |
24 |
5.373 ± 1.382 (25.72%) |
| 3 (N=6) |
27 MIU |
SR-IFN-α |
65.73 ± 6.702 (10.20%) |
24 |
5.544 ± 0.5509 (9.94%) |
| 4 (N=6) | 36 MIU | SR-IFN-α | 80.31 ± 9.859 (12.28%) | 24 | 7.151 ± 1.132 (15.83%) |
aThere was not a separate control group, but data from a total of eight subjects (two subjects in each of the four groups) who received 3 MIU of Roferon-A® were shown.